Tunlametinib combo for KRAS-mutated advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination treatment with tunlametinib for people with a specific type of advanced non-small cell lung cancer (NSCLC) that has a KRAS mutation and has not responded to standard therapy. The goal is to see if this targeted therapy can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with advanced or metastatic non-small cell lung cancer (NSCLC) that cannot be removed with surgery.
- Your cancer has a KRAS mutation (including G12C or other types).
- You have tried standard first-line treatment, and it no longer works or caused bad side effects.
- You have at least one tumor that can be measured on a scan.
- You are in good enough health to be active and care for yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (Tunlametinib and an anti-EGFR antibody) in people with advanced pancreatic or colorectal cancer that has a RAS mutation and has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial studies a combination of two targeted drugs (Tunlametinib and Fruquintinib) for people with advanced colorectal cancer that has a RAS mutation and has not responded to two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs (trametinib, anlotinib, and tislelizumab) for people with KRAS-mutant non-small cell lung cancer that has progressed after one prior treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests an experimental pill (Tunlametinib) for people with solid tumors that have a specific NRAS gene change and have stopped responding to other treatments. The goal is to see if the drug can shrink or slow the growth of these tumors.
This trial tests a new oral targeted therapy (Tunlametinib) for people with advanced melanoma that has a specific gene change called NRAS. It's for those who have already tried immunotherapy and need another option.
This study tests a combination of two targeted pills (tunlametinib and vemurafenib) for people with metastatic colorectal cancer that has a specific gene change (BRAF V600E) and whose cancer has grown after at least one prior treatment. The goal is to see if this drug combination can shrink tumors or slow cancer growth.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.